Neurochemical dementia diagnostics: State of the art and research perspectives.
The aim of this review is to present current state of the art on the field of routine neurochemical dementia diagnostics (NDD) with a focus on cerebrospinal fluid (CSF) biomarkers: amyloid beta peptides, tau protein, and its phosphorylated form (pTau). After several years of experience, it is reasonably to postulate that CSF biomarkers analysis is an increasingly important tool within the early and differential diagnosis of dementia syndromes. Actual research activities are briefly discussed, too, including: (i) possibilities and limitations of the diagnosis of incipient Alzheimer's disease in preclinical stages (e.g., mild cognitive impairment), (ii) the role of multiplexing technologies in dementia biomarkers research, (iii) the role of biomarkers in differential diagnosis of dementia syndromes, (iv) approaches to improve analytical performance of available methods, and (v) research activities to identify dementia biomarkers in blood.
Lewczuk
Piotr
P
Department of Psychiatry and Psychotherapy, Universitätsklinikum Erlangen, Erlangen, Germany.
Wiltfang
Jens
J
D000544:Alzheimer Disease / Q000134:cerebrospinal fluid / Q000175:diagnosis; D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid; D015415:Biomarkers / Q000134:cerebrospinal fluid; D003704:Dementia / Q000134:cerebrospinal fluid* / Q000175:diagnosis*; D003937:Diagnosis, Differential; D006801:Humans; D010766:Phosphorylation; D016875:tau Proteins / Q000134:cerebrospinal fluid / Q000378:metabolism
D016229:Amyloid beta-Peptides; D015415:Biomarkers; D016875:tau Proteins